RRT With a Cytokine Absorption Filter (oXiris ®) in Patients With Septic Shock

CompletedOBSERVATIONAL
Enrollment

93

Participants

Timeline

Start Date

September 1, 2021

Primary Completion Date

June 1, 2023

Study Completion Date

November 10, 2023

Conditions
Acute Kidney InjurySeptic Shock
Interventions
DEVICE

Oxiris

Through a previously established and standardized management protocol, the treating team will prescribe renal replacement therapy by hemodiafiltration (CVVHDF) in the PrismaFlex device, at a dose of 25 mL / Kg of PrismaSate dialysis solutio and the removal filter oXiris® cytokines (Baxter) vs. the standard filter.

Trial Locations (1)

050012

Clinica CES, Medellín

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Baxter Healthcare Corporation

INDUSTRY

lead

Clinica CES

NETWORK

NCT04952714 - RRT With a Cytokine Absorption Filter (oXiris ®) in Patients With Septic Shock | Biotech Hunter | Biotech Hunter